WO2005079766A3 - Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds - Google Patents

Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds Download PDF

Info

Publication number
WO2005079766A3
WO2005079766A3 PCT/DK2005/000098 DK2005000098W WO2005079766A3 WO 2005079766 A3 WO2005079766 A3 WO 2005079766A3 DK 2005000098 W DK2005000098 W DK 2005000098W WO 2005079766 A3 WO2005079766 A3 WO 2005079766A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue factor
therapeutic combination
cancer compounds
factor antagonist
relates
Prior art date
Application number
PCT/DK2005/000098
Other languages
French (fr)
Other versions
WO2005079766A2 (en
Inventor
Joern Roland Mueller
Original Assignee
Novo Nordisk As
Joern Roland Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Joern Roland Mueller filed Critical Novo Nordisk As
Priority to EP05700648A priority Critical patent/EP1744734A2/en
Priority to JP2006553435A priority patent/JP2007523099A/en
Publication of WO2005079766A2 publication Critical patent/WO2005079766A2/en
Publication of WO2005079766A3 publication Critical patent/WO2005079766A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a novel pharmaceutical compositions comprising a combination of a compound, which binds to and inhibits the activity of tissue factor and a chemotherapeutic compound. The invention also relates to their use in the prophylaxis or treatment of diseases or disorders related to patho-physiological tissue factor (TF) functions.
PCT/DK2005/000098 2004-02-20 2005-02-14 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds WO2005079766A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05700648A EP1744734A2 (en) 2004-02-20 2005-02-14 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
JP2006553435A JP2007523099A (en) 2004-02-20 2005-02-14 Combination therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400264 2004-02-20
DKPA200400264 2004-02-20

Publications (2)

Publication Number Publication Date
WO2005079766A2 WO2005079766A2 (en) 2005-09-01
WO2005079766A3 true WO2005079766A3 (en) 2005-10-13

Family

ID=34878005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000098 WO2005079766A2 (en) 2004-02-20 2005-02-14 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds

Country Status (3)

Country Link
EP (1) EP1744734A2 (en)
JP (1) JP2007523099A (en)
WO (1) WO2005079766A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5855326B2 (en) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス Anti-KIR combination therapy and method
US8372810B2 (en) 2007-04-11 2013-02-12 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
DE602007009797D1 (en) * 2007-04-11 2010-11-25 Gene Signal Int Sa Antitumor remedy, medicament, composition and use thereof
ATE552271T1 (en) * 2007-04-11 2012-04-15 Gene Signal Int Sa ANTITUMOR MEDICINE, DRUG, COMPOSITION AND USE THEREOF
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
RS56599B1 (en) 2010-06-15 2018-02-28 Genmab As Human antibody drug conjugates against tissue factor
KR102046666B1 (en) 2011-05-25 2019-11-19 이나뜨 파르마 Anti-kir antibodies for the treatment of inflammatory disorders
JOP20200308A1 (en) 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules
US10894075B2 (en) * 2013-03-15 2021-01-19 GLAdiator Biosciences, Inc. Gla domains as targeting agents
BR112018000903A2 (en) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. compositions and methods for cancer treatment
CN114184792A (en) * 2021-11-17 2022-03-15 中国人民解放军总医院第二医学中心 Coronary heart disease marker IL-29 and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004148A1 (en) * 1998-07-15 2000-01-27 Genentech, Inc. Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
WO2001001749A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. FVIIa ANTAGONISTS
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004148A1 (en) * 1998-07-15 2000-01-27 Genentech, Inc. Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
WO2001001749A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. FVIIa ANTAGONISTS
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 101b, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2003 (2003-11-16), NIMEIRI HALLA ET AL: "Severe retro pharyngeal bleeding in a patient with acquired Factor FVIII inhibitor.", XP002339029, Database accession no. PREV200400161757 *
KIRCHHOFER D ET AL: "EPITOPE LOCATION ON TISSUE FACTOR DETERMINES THE ANTICOAGULANT POTENCY OF MONOCLONAL ANTI-TISSUE FACTOR ANTIBODIES", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 84, no. 6, December 2000 (2000-12-01), pages 1072 - 1081, XP001041490, ISSN: 0340-6245 *
MILLER DEBRA L ET AL: "Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 26, no. 6, June 2002 (2002-06-01), pages 650 - 658, XP002337200, ISSN: 1044-1549 *
PERSSON E ET AL: "Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 40, no. 11, 20 March 2001 (2001-03-20), pages 3251 - 3256, XP002311730, ISSN: 0006-2960 *
ZHIWEI HU ET AL: "Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 21, 2 October 2002 (2002-10-02), pages 12180 - 12185, XP002262739, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2005079766A2 (en) 2005-09-01
JP2007523099A (en) 2007-08-16
EP1744734A2 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
WO2005079766A3 (en) Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2005072308A3 (en) Cgrp receptor antagonists
WO2006098969A3 (en) Quinazolinone t-type calcium channel antagonists
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2006116733A3 (en) Protein kinase inhibitors
MY146388A (en) Thiazole pyrazolopyrimidines as crfi receptor antagonists
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2007061692A3 (en) Spirolactam tricyclic cgrp receptor antagonists
MX2009008363A (en) Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist.
TW200726763A (en) Novel compound
MXPA05011858A (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use.
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2007006790A3 (en) Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005700648

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006553435

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005700648

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005700648

Country of ref document: EP